Christine Humblet

With her doctorate degree in Chemistry, Christine spent her early career days in academia where she developed and applied computer-assisted molecular modeling techniques while building the foundation and blueprint for the software Sybyl, later commercialized by Tripos Inc. Her research focused in the Pain, Neurosciences and Cardiovascular areas to elucidate structure-activity patterns for fentanyl, gabapentin, serotonin inhibitors among others.

She transitioned to the Pharmaceutical Industry, initially as an individual contributor and grew into an exceptional scientific and technical leader in her field. Her journey began at Parke-Davis in Ann Arbor, Michigan. Since her early days in molecular modeling and drug design, Christine has been a champion and advocate in pioneering the use of structure-based design, 3-dimensional molecular visualization and integrated platforms to analyze target families with ligand-based structure-activity data.

By systematically applying predictive approaches with medicinal chemistry desktop modeling tools, she has positively impacted therapeutics discovery as evidenced by more than 115 publications. Most recently, she led cheminformatics initiatives to transform drug discovery through artificial intelligence and machine learning techniques.

Throughout her career, she has led multiple scientific collaborations with leading academic and industrial partners. She tutored and mentored multiple group members who progressed in successful careers.